Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients With HER2-Positive Solid Tumors

NCT04189211 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT04189211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients With HER2-Positive Solid Tumors
Lead sponsor
Bio-Thera Solutions
Phase
Phase 1
Overall status
Unknown status
Start date
March 7, 2017
Completion date
December 31, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive solid tumors